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Quantitative assays for human DNA and mRNA were
used to examine the paradox that intravenously (i.v.)
infused human multipotent stromal cells (hMSCs)
can enhance tissue repair without significant engraft-
ment. After 23 106 hMSCswere i.v. infused intomice,
most of the cells were trapped as emboli in lung. The
cells in lung disappeared with a half-life of about
24 hr, but <1000 cells appeared in six other tissues.
ThehMSCs in lungupregulatedexpressionofmultiple
genes, with a large increase in the anti-inflammatory
proteinTSG-6.Aftermyocardial infarction, i.v. hMSCs,
but not hMSCs transduced with TSG-6 siRNA,
decreased inflammatory responses, reduced infarct
size, and improved cardiac function. I.v. administra-
tion of recombinant TSG-6 also reduced inflammatory
responses and reduced infarct size. The results
suggest that improvements in animal models and
patients after i.v. infusions of MSCs are at least in
part explained by activation of MSCs to secrete
TSG-6.
INTRODUCTION
Currently there is interest in developing new therapies with cells
that can repair nonhematopoietic tissues (Caplan, 2007; Gior-
dano et al., 2007; Prockop and Olson, 2007). Among the cells
being tested are the adult stem/progenitor cells from bone
marrow initially referred to as fibroblastic colony-forming units,
then as marrow stromal cells, subsequently as mesenchymal
stem cells, and most recently as multipotent mesenchymal
stromal cells or MSCs (Dominici et al., 2006). The first clinical
trials with MSCs were in osteogenesis imperfecta (Horwitz
et al., 1999), then in lysosomal storage diseases (Koc et al.,
1999), and subsequently in graft versus host disease (Le Blanc
and Ringden, 2006). Currently MSCs are being employed in clin-
ical trials in heart disease, Crohn’s disease, cartilage repair,
stroke, spinal cord injury, and several other diseases (Prockop
and Olson, 2007; Caplan, 2007; Giordano et al., 2007). In many
of the experimental animal models and in clinical trials, the cells54 Cell Stem Cell 5, 54–63, July 2, 2009 ª2009 Elsevier Inc.were intravenously (i.v.) infused (Pereira et al., 1998; Horwitz
et al., 1999; Akiyama et al., 2002; Koc et al., 2002; Nomura
et al., 2005; Le Blanc et al., 2007; Wu et al., 2008). The functional
improvements were surprising, sinceMSCs infused i.v. into mice
or rats were rapidly trapped in lung (Gao et al., 2001; Schrepfer
et al., 2007) as microemboli that are potentially lethal (Lee
et al., 2009). Trapping of MSCs in the lung is not in itself unex-
pected, since the cells tightly adhere to culture plasticware and
to each other as they are expanded in culture (Colter et al.,
2001; Owen and Friedenstein, 1988). Also, trapping of cells in
lungs occurs with metastatic tumors (Khanna et al., 2004) and
probably hematopoietic stem cells (Dooner et al., 2004). How-
ever, it was not clear howMSCs trapped in the lung can enhance
repair of the heart, brain, and other tissues.
Here we first developed assays to provide quantitative data on
the fate of human cells infused into mice. We then demonstrated
that i.v.-infused human MSCs (hMSCs) produced functional
improvement in mice with myocardial infarction (MI) at least in
part because the cells trapped as emboli in lung are activated
to express the anti-inflammatory factor TNF-a-induced protein
6 (TNAIP6 or TSG-6).
RESULTS
Clearance from Blood and Trapping of Systemically
Infused hMSCs
To follow the fate of hMSCs infused i.v. into mice, we used real-
time PCR assays for human-specific Alu sequences (McBride
et al., 2003). After i.v. infusion of 2 3 106 hMSCs, the Alu assay
indicated that 99% ± 1.07% SD of the cells were cleared from
the circulation within 5 min (Figure 1A). From 2% to 3% of the
cells (4–6 3 104) reappeared in the circulation after a lag period
of about 10 min, apparently after release from the lung. To verify
that the small number of Alu sequences detected in blood
reflected hMSCs, 50 ml of peripheral blood recovered after
15 min was plated on plastic culture dishes in hMSC medium
and incubated for 14 days. The cultures generated typical colo-
nies of spindle-shaped hMSCs that were labeled with antibodies
to both human nuclei antigen and human b2-microglobulin (see
Figure S1 available online). To follow the distribution of the cells
in tissues, we developed individual standard curves for each
tissue by adding varying numbers of hMSCs to the tissues
from naive mice just before homogenization (Figure 1B). The
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troduced by differences in yields of extracted DNA, cell numbers
of the organs, or efficiencies of the PCR reactions. The sensitivity
of the assay was about 100 human cells per mouse organ
assayed. To facilitate the assay, a quantitative colorimetric assay
for DNA in extracts (Burton, 1956) was used instead of UV absor-
bance to select appropriate aliquots for the PCR reactions. As
expected (Gao et al., 2001; Schrepfer et al., 2007; Lee et al.,
2009), most of the cells cleared from the circulation were trapped
in the lung. In mice sacrificed after 15min, 83%± 6.3%SD of the
human DNAwas recovered in lung, and only trace amounts were
recovered in other tissues (Figure 1C). Similar results were
obtained in control experiments with i.v. infusions of a line of
metastatic breast carcinoma cells (MDA-MB-231 in Figure 1C).
After i.v. infusion of human white blood cells, a smaller fraction
was recovered in lung after 15 min, and larger numbers both
remained in circulation and appeared in liver (Figure 1C). The
fraction of hMSCs trapped in the lung was not significantly
reduced by decreasing the number of infused MSCs to as little
as 10,000 in the same volume of vehicle (150 ml), pretreating
the cells with antibodies to integrin-a4 or integrin-a6 (Qian
et al., 2006), or preincubating the cells with rat white blood cells
Figure 1. Assays for Fate of hMSCs Infused
into Mice
(A) Clearance of human Alu sequences from blood
after i.v. infusion of about 2 3 106 hMSCs into
mice. Values are means ± SD; n = 6.
(B) Standard curves for real-time PCR assays of
humanAlusequences in sevenorgans. Values indi-
cate DDCt for primers for mouse/human GAPDH
genes and Alu sequences on same samples.
(C) Tissue distribution of human Alu sequences
15 min after i.v. infusion of about 2 3 106 hMSCs
into mice. Values are means ± SD; n = 6.
(D) Standard curves for real-time RT-PCR assays
of human mRNA for GAPDH. Values indicate
DDCt for primers for mouse/human GAPDH genes
and cDNA for human-specificGAPDHon the same
samples.
(E) Kinetics of hMSCs in lung and six other tissues
after i.v. infusion of about 2 3 106 hMSCs. Values
are means ± SD; n = 6.
(F) Appearance of hMSCs in heart after i.v. infusion
of about 1 3 106 hMSCs 1 day after permanent
ligation of the left anterior descending coronary
artery.
(Chute, 2006). To examine effects of arte-
rial infusion, 23 106 hMSCs were infused
into the left ventricle of the heart. Most of
the cells were again cleared from the
blood in 5 min (Figure S2A), but there
again was a small recirculation of about
1.72% ± 1.81% SD of the infused cells
for 15–60 min (Figure S2A). Also, in com-
parison to i.v. infusions, larger numbers of
the cells were recovered in organs such
as brain, heart, lung, liver, and kidney
15 min after the infusions (Figure S2B).
Control experiments with breast meta-
static cancer cells produced a similar pattern of tissue distribu-
tion (Figure S2B).
For a semiquantitative assay for viable cells (Nishida et al.,
2006), a similar strategy was used to develop a quantitative
RT-PCR assay specific for human GAPDH mRNA (Figure 1D).
The assay had about the same sensitivity as the Alu assay but
required more manipulation of the samples. Data developed
with the assay indicated that the distribution of Alu sequences
largely reflected live cells (Figures 1E and 1F).
Kinetics and Redistribution of hMSCs Trapped in Lung
To examine the redistribution with time of the cells from lung,
23 106 hMSCs were infused i.v., and seven tissues of mice were
assayed for up to 4 days (Figure 1E). Assays for Alu sequences
indicated that the cells initially trapped in lung disappeared
with a half-life of about 24 hr. Similar values were obtained by
assays for viable human cells by the levels of human mRNA for
GAPDH (Figure 1E). Histological sections of lung demonstrated
that the hMSCs trapped in lung formed emboli in afferent blood
vessels (Lee et al., 2009), with many of the cells undergoing
apoptosis (data not shown). The cells that disappeared from
lung did not appear in any significant numbers in the six otherCell Stem Cell 5, 54–63, July 2, 2009 ª2009 Elsevier Inc. 55
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to about 4000 cells) were recovered in the six tissues after 48 hr
and 0.01% after 96 hr (Figure 1E).
Trapping of hMSCs in Infarcted Heart
To determine whether larger numbers of i.v.-infused hMSCs
appeared in the heart after MI, hMSCs were infused into the
tail veins for NOD/SCID mice 1 day after MIs were produced
by permanent ligation of the anterior descending coronary artery
(LAD). Assays for Alu sequences indicated that 0.04% ± 0.03%
SD of the infused cells (400 cells ± 300 SD; n = 5) were recovered
in the infarcted hearts 15 min after the infusion (Figure 1F). One
day after i.v. infusions, the Alu sequences in heart increased
about 5-fold to 0.148% ± 0.053% SD, equivalent to about
1480 cells ± 530 SD (n = 5). Similar values were obtained
by assays for human GAPDH mRNA (792 cells ± 140 SD; n = 5)
1 day after the infusions.
Figure 2. Heat Map of Microarray Assays of
Mouse Lungs after I.v. Infusion of hMSCs
About 2 3 106 hMSCs were infused i.v., and lung
RNA was recovered 10 hr later for assays on
bothmouse-specific and human-specificmicroar-
rays (Affymetrix, Santa Clara, CA). Data were
filtered for cross-hybridization (CV > 0.5 and
call > 33%), analyzed with the Microarray Suite
5.0 program, and normalized to a value of 1 and
variance of 3 SD (+3, red; 3, blue). Gene ontology
categories of genes are indicated. The number of
genes with expression differences is indicated in
the boxes.
(A) Assay on mouse-specific chip.
(B) Assay of same RNA on human-specific chip.
Symbols: con, lung from control mouse; hMSCs
con, sample of hMSCs added to lung from control
mouse before extraction of RNA; hMSCs i.v.,
sample from mouse lung 10 hr after i.v. infusion
of hMSCs.
Changes in the Mouse and Human
Transcriptome Produced
by Embolization
To assay both transcriptomes, about 2 3
106 hMSCswere infused into the tail veins
of mice, and RNA was extracted from
lung 10 hr later, a time at which assays
for human GAPDH mRNA indicated there
were adequate amounts of human mRNA
for assays (Figure 1E). After filtering for
cross-hybridization with human mRNA
(see the Supplemental Data), the data
indicated that embolization with the
hMSCs upregulated expression of 755
mouse transcripts and downregulated
expression of 347 mouse transcripts
2-fold or more (Figure 2A). Also, the data
indicated that after embolization in lung,
451 human transcripts were upregulated
and 1009 transcripts were downregulated
(Figure 2B).
The upregulated 451 human transcripts were subjectively
examined for candidate genes of interest, and human-specific
real-time RT-PCR assays were used to confirm the microarray
data (Figure 3A). The results confirmed 2-fold or greater
increases in the transcripts for SMAD6, CSF1, VCAM-1, and
TNFAIP6 (TSG-6). The increases in TSG-6 were 28-fold and
47-fold or considerably larger than the 7.5-fold increase
detected by the microarrays (Table S1). As recently reported
(Ylostalo et al., 2008), real-time RT-PCR assays frequently
demonstrated larger changes in transcripts than microarray
assays with the system employed here.
MSCs In Vitro Are Activated to Secrete TSG-6
The increase in TSG-6 was of particular interest because the
protein was previously shown to be a powerful anti-inflammatory
factor (Forteza et al., 2007; Getting et al., 2002; Wisniewski and
Vilcek, 2004; Milner et al., 2006). Real-time RT-PCR assays56 Cell Stem Cell 5, 54–63, July 2, 2009 ª2009 Elsevier Inc.
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TSG-6
(A) Real-time RT-PCR assays for human-specific
mRNAs in lung 10 hr after i.v. infusion of 2 3 106
hMSCs. Values are fold increase over values
for cultured hMSCs, normalized by DDCt for
hGAPDH. Symbols: hMSCs con, sample of
hMSCs added to lung from control mouse before
extraction of RNA; hMSCs i.v. 1 and 2, samples
from lungs of two mice 10 hr after i.v. infusion of
hMSCs.
(B) Real-time RT-PCR assays for human TSG-6 in
mouse lung. About 2 3 106 hMSCs were infused
i.v. into naive mice (IV-nor) or mice at 1 hr after
MI (IV-MI), and lungs were recovered 0.25–24 hr
after the infusions. Values are ± SD; n = 2 or 3 for
normal mice; n = 6 for MI mice.
(C) Real-time RT-PCR assays for TSG-6 in hMSCs
and human fibroblasts from the same donor
incubated in serum-free medium with 10 ng/ml
TNF-a for 24 or 48 hr. Results with two passages
of the same cells are shown. Values are ± SD;
n = 3.
(D) ELISA assays for TSG-6 in medium from
hMSCs and human fibroblasts incubated in
serum-free medium with 10 ng/ml TNF-a for 48
hr. Values are ± SD; n = 3.
(E) Real-time RT-PCR assays TSG-6 of control
hMSCs (Con), hMSCs treated with transfection
reagents only (no siRNA), hMSCs transfected
with a scrambled siRNA (scr siRNA), or hMSCs
transduced with TSG-6 siRNA (TSG-6 siRNA).
Cells were incubated with or without 10 ng/ml
TNF-a for 6 hr. Values are ± SD; n = 3.
(F) ELISA assays for TSG-6 in medium after incu-
bation of cells with or without TNF-a for 48 hr.
Symbols are as in (E). Values are ± SD; n = 3.demonstrated that human TSG-6mRNA in lung was increased at
10 hr and further increased at 24 hr after i.v. infusions of hMSCs
(Figure 3B). There was no difference in expression of TSG-6 in
lungs from naive mice and mice with MIs (Figure 3B). TSG-6
was discovered by analysis of cDNA clones from skin fibroblasts
that were incubated with TNF-a (Lee et al., 1992). Therefore,
hMSCs and fibroblasts from same donor were incubated with
TNF-a, and the mRNAs were assayed by real-time RT-PCR.
The transcript for TSG-6 in hMSCs was increased about 120-
fold after incubation with 10 ng/ml TNF-a for 48 hr and increased
about 80-fold with a further passage of the hMSCs (Figure 3C).
ELISAs indicated that incubation with TNF-a for 48 hr increased
the secretion of TSG-6 protein from undetectable levels to over
2000 pg/ml per 105 cells per 48 hr (Figure 3D). Surprisingly, the
response of hMSCs to TNF-a far exceeded the response of
human fibroblasts. In parallel experiments, mouse MSCs incu-
bated with TNF-a under the same conditions upregulated ex-
pression of the transcript for TSG-6 3.94-fold (±0.49 SD; n = 4).
Transient transduction of hMSCswith TSG-6 siRNA abrogated
the effects of TNF-a on TSG-6 transcription (Figure 3E) and
secretion (Figure 3F). Expression of TSG-6 was partially reduced
by amock transduction or transduction with a scrambled siRNA.Both I.v. MSCs and rhTSG-6 Decrease Proinflammatory
Proteases in Mice with MI
Acute MI produces an acute inflammatory response in which
infiltrating neutrophils generate MMPs that degrade the myocar-
dium (Fang et al., 2007; Lindsey et al., 2001). The permanent LAD
increased serum levels of both cardiac troponin I (Figure 4A), a
biomarker for myocardial injury (Chapelle, 1998; Pervaiz et al.,
1997), and plasmin activity (Figure 4B), amarker for inflammatory
responses (Heymans et al., 1999; Griffin et al., 2005). The
plasmin activity was decreased by two infusions of rhTSG-6,
an observation consistent with its known inhibitory effects (Bar-
dos et al., 2001; Milner et al., 2006). The plasmin activity was also
decreased by i.v. infusion of hMSCs and hMSCs with a scram-
bled siRNA, but not hMSCs transduced with siRNA for TSG-6.
As expected (Fang et al., 2007), the enzymic activities of both
pro-MMP9 and activeMMP9were increased in heart 2 days after
MI (Figure 4C). I.v. infusion of hMSCs or hMSCs transduced with
a scrambled siRNA decreased both activities (Figure 4C). The
effects of hMSCs were partially negated by knockdown of the
TSG-6 gene prior to infusion of the cells. Also, the effects of
hMSCs were partially duplicated by the two infusions of human
recombinant TSG-6. The decreases in pro-MMP activities wereCell Stem Cell 5, 54–63, July 2, 2009 ª2009 Elsevier Inc. 57
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the heart (Figures 4D and 4E).
Effects of TSG-6 on Infarct Size and Heart Function inMI
As reported previously (Iso et al., 2007), i.v. infusion of hMSCs
decreased infarct size examined 3 weeks after MI (Figures 5A,
5B, and 5F and Figure S3). hMSCs with an siRNA knockdown
of the TSG-6 gene had no effect on infarct size (Figures 5D
and 5F). hMSCs transducedwith the scrambled siRNAproduced
an intermediate effect on infarct size (Figures 5C and 5F), appar-
Figure 4. Assays of Serum and Heart
(A) Assay for cardiac troponin I in serum 48 hr after
MI. Values are ± SD; **p < 0.01 with n = 3 (normal)
or six mice (MI) per group.
(B) Plasmin activity in serum 48 hr after MI.
Symbols: Normal, naive mice; –, MI only; hMSCs,
23 106 hMSCs infused i.v. 1 hr after MI; scr siRNA,
23 106 hMSCs transduced with scrambled siRNA
infused i.v. 1 hr after MI; TSG-6 siRNA, 2 3 106
hMSCs transduced with TSG-6 siRNA infused
i.v. 1 hr after MI; rhTSG-6, 30 mg rhTSG-6 protein
infused i.v. 1 hr and again 24 hr after MI. Values
are ± SD; **p < 0.01 with n = 3 mice per group.
N.S., not significant.
(C) Hearts assayed for pro- and active-matrix
MMP9 on a gelatin zymogen gel 48 hr after MI.
Image is reversed. Symbols are as in (B).
(D and E) Granulocyte and monocyte infiltration in
the heart 48 hr after MI. Sections stained with anti-
Ly-6G and Ly-6C. Symbols are as in (B), except
that 100 mg rhTSG-6 protein was infused i.v. 1 hr
and again 24 hr after MI. Magnification 34. Scale
bars, 250 mm. Values are ± SD; n = 3 or 4 for
each group. **p < 0.001; N.S., not significant.
ently because the scrambled siRNA had
a partial effect on TSG-6 secretion
(Figures 3E and 3F). In addition, i.v. infu-
sion of 100 mg of rhTSG-6 immediately
following the surgery and at 24 hr also
decreased infarct size (Figures 5E and
5F and Figure S3). However, the effect
of rhTSG-6 was somewhat less than the
decrease in infarct size following admin-
istration of the hMSCs (p < 0.05).
Assays by echocardiography demon-
strated comparable effects on heart func-
tion. I.v. infusions of 2 3 106 hMSCs or
hMSCs with a scrambled siRNA 1 hr after
MI produced significant improvements in
percent left ventricular fractional short-
ening and left ventricular ejection fraction
in hearts assayed 3 weeks later (Figure 6
and Table S3). Infusions of hMSCs with
a knockdown of TSG-6 had no effect.
DISCUSSION
The hMSCs trapped in mouse lung after
i.v. infusion underwent major changes in
their patterns of gene expression in response to the injury to
the lung produced by microembolization of the cells in the
pulmonary vasculature (Furlani et al., 2009; Lee et al., 2009).
The upregulation of the human TSG-6 was of special interest
because of the known anti-inflammatory effects of the protein
(Milner et al., 2006; Wisniewski and Vilcek, 2004) and because
excessive inflammatory responses contribute to the pathological
changes produced by MI (Ovechkin et al., 2005; Paolocci et al.,
2006; Carvalho et al., 2006; Fang et al., 2007; Moshal et al.,
2008). Therefore, the results suggested a possible explanation58 Cell Stem Cell 5, 54–63, July 2, 2009 ª2009 Elsevier Inc.
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function in models for MI (Halkos et al., 2008; Iso et al., 2007;
Krause et al., 2007; Wolf et al., 2007). In the mouse model for
MI, knockdown of TSG-6 expression in hMSCs largely negated
the improvements in inflammatory responses, infarct size, and
cardiac function produced by i.v. fusions of hMSCs. In addition,
i.v. infusions of rhTSG-6 largely duplicated the therapeutic
effects of the hMSCs on inflammatory responses and infarct
size. Therefore, the results indicated that the hMSCs that were
trapped in the lung were activated to secrete TSG-6, and the
TSG-6 suppressed the excessive inflammatory response to
LAD so as to decrease the proteolytic damage to the heart and
the subsequent fibrotic scarring and decrease in cardiac func-
tion. The 1500 or so of hMSCs transiently appeared in the
infracted heart after infusion of 106 hMSCs may also have
contributed to the anti-inflammatory effects.
The upregulation of TSG-6 was detected by the cross-species
strategy of infusing hMSCs into NOD/SCID mice. Similar strate-
gies of using hMSCs in animal models previously proved useful,
because the hMSCs provided numerous endogenous markers
for the cells and no obvious cross-species artifactswere encoun-
tered (Hwang et al., 2008; Lu et al., 2009; Bai et al., 2009; Gonza-
Figure 5. Assays of Infarct Size
Each heart was cut from the apex through the base into over 400 sequential
5 mm sections and stained with Masson Trichrome. Every twentieth section
is shown. Additional heart samples are shown in Figure S3.
(A–E) Symbols are as in Figure 4B, except that 100 mg rhTSG-6 protein was
infused i.v. 1 hr and again 24 hr after MI.
(F) Infarct size measurements (%) obtained by midline length measurement
from tenth section of the infarct area for a total of 20 sections per heart
(Takagawa et al., 2007). Values are ± SD; n = 3 or 4 mice in each group;
***p < 0.0001 compared to MI controls; N.S., not significant compared to MI
controls; *p < 0.05 for MI + MSCs versus MI + rhTSG-6.lez-Rey et al., 2009; Sasportas et al., 2009), apparently because
of the immunemodulatory effects of the cells (Uccelli et al., 2008).
Also, the strategy of using hMSCs avoids the technical difficulties
of isolatingmouseMSCs (Baddooet al., 2003;Gnecchi andMelo,
2009; Peister et al., 2004; Sung et al., 2008) and the marked
tendency of mouse MSCs to develop genomic instability and
become tumorgenic as they are expanded in culture (Sung
et al., 2008; Tolar et al., 2007). Permanent LAD ligation in mice
does notmimic humanMI as closely as ischemia and reperfusion
models in larger animals. However, permanent LAD ligation in
NOD/SCID mice provided a useful model for testing the effects
on hMSCs because the mice retained the excessive inflamma-
tory responses to MI (Iso et al., 2007).
TSG-6 is a 30 kDa glycoprotein (Heng et al., 2008; Milner et al.,
2006) that was shown to produce three distinct anti-inflamma-
tory effects (Milner et al., 2006; Wisniewski and Vilcek, 2004):
(1) it inhibits the inflammatory network of proteases primarily
by increasing the inhibitory activity of inter-a-inhibitor, (2) it binds
to fragments of hyaluronan and thereby blunts their proinflam-
matory effects, and (3) it inhibits neutrophil infiltration into sites
of inflammation. In transgenic mice, inactivation of the gene
increased inflammatory responses (Szanto et al., 2004), and
overexpression of the gene decreased inflammatory responses
(Mindrescu et al., 2002). Also, administration of the recombinant
protein improved arthritis in several murinemodels (Bardos et al.,
Figure 6. Echocardiographic Assays 3 Weeks after MI
(A) Representative M-mode echocardiograms. Symbols are as in Figure 4B.
(B) Left ventricular fractional shortening (LVFS) and left ventricular ejection
fraction (LVEF) from echocardiographic data. Values are ± SD; n = 5 or 6 for
each group; *p < 0.05 versus MI; N.S., not significant.Cell Stem Cell 5, 54–63, July 2, 2009 ª2009 Elsevier Inc. 59
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discovered by screening cDNA libraries from fibroblasts incu-
bated with TNF-a (Lee et al., 1992), the results here demon-
strated that hMSCs produced far more TSG-6 in response to
TNF-a than dermal fibroblasts.
The results do not exclude the possibility that the hMSCs trap-
ped in lung secreted additional cardioprotective factors in addi-
tion to TSG-6. The effects of rhTSG-6 on infarct size in the mice
were slightly less than the effects of i.v. infusions of hMSCs.
MSCs in culture and in response to chemokines or injured cells
secrete large amounts of therapeutic factors such as TGF-b,
HGF, IL-4, IL-10, PGE2, and stanniocalcin-1 (Caplan, 2009;
Gnecchi et al., 2008; Block et al., 2009; Ohtaki et al., 2008).
TSG-6 may, however, play a key role in many beneficial effects
of MSCs. Inflammatory responses to sterile tissue injury are
frequently excessive and require active suppression (Schwab
et al., 2007). Also, chronic inflammation plays a key role in
diseases such as diabetes, stroke, Alzheimer’s disease, and
Parkinson’s disease (Bergsbaken et al., 2009; McCombe and
Read, 2008; Shoelson et al., 2006; Theuma and Fonseca,
2004). Therefore, secretion of TSG-6 byMSCs trapped as emboli
in lung may in part explain the therapeutic effects observed after
i.v. infusions of MSCs in animal models for these and other
diseases (Uccelli et al., 2008; Ezquer et al., 2008; Parr et al.,
2007). Secretion of TSG-6 may also play a role in therapies for
heart disease with other cells such as skeletal myoblasts, fetal
myoblasts, and embryonic stem cells (Jolicoeur et al., 2007).
EXPERIMENTAL PROCEDURES
Cell Preparations
hMSCs and mouse MSCs from bone marrow were obtained from the Center
for the Preparation and Distribution of Adult Stem Cells (formerly http://
www.som.tulane.edu/gene_therapy/distribute.shtml; currently available by
contacting msc@medicine.tamhsc.edu). The center has supplied standard-
ized preparations of MSCs enriched for early progenitor cells to over 250 labo-
ratories under the auspices of a National Institutes of Health/National Center
for Research Resources (NIH/NCRR) grant (P40 RR 17447-06). The hMSCs
were expanded to passage 3 and 70% confluency and the mouse MSCs
cultures as indicated in the Supplemental Data. Source and conditions for
culture of human breast carcinoma cells and fibroblasts are also presented
in the Supplemental Data.
I.v. Infusion of hMSCs
Mice were anesthetized, and 150 ml of a suspension of about 1 or 2 3 106
hMSCswas infused with a 28 gauge needle either through a tail vein or through
the chest wall into the left ventricle. Successful i.v. infusion was monitored by
lack of extravasation at the site and recoveries of about 80% of the Alu
sequences in lung within the first hour of infusion (Figure 1C). Prior to infusion,
the cells were maintained at 4C, and they were gently resuspended with
a pipette to ensure they were not aggregated before infusion.
Isolations of DNA and RNA
Blood samples of 50 ml were withdrawn with a needle and syringe from the left
ventricle of the heart and adjusted to 2 mM EDTA. The mice were then
perfused through the left ventricle with 20 ml of PBS and then through the right
ventricle with 5 ml of PBS. Brain, heart, lung, liver, pancreas, spleen, kidney
tissues, and bone marrow were isolated by dissection and stored at 80C.
To extract DNA, the samples were thawed and added to in 5 ml buffer
(10 mM Tris HCl [rO 8.0] containing 20 ml Proteinase K [10 mg/ml], 0.1 mM
EDTA [rO 8.0], 0.5% SDS, and 20 ug/ml RNase A). The samples were homog-
enized (PowerGenModel 125Homogenizer; Fisher Scientific) and incubated in
a shaker at 200 rpm and 50C overnight. DNA was extracted by mixing 0.5 ml
of sample with 0.5 ml phenol/chloroform solution (pH 6.7) and centrifugation at60 Cell Stem Cell 5, 54–63, July 2, 2009 ª2009 Elsevier Inc.15,3003 g for 5 min in 2 ml phase lock gel tubes (Phase Lock Gel; Eppendorf/
Brinkmann Instruments, Inc). DNA was precipitated with half volume of 2.5 M
ammonium acetate and same volume of 100% ethanol overnight at 4C. The
precipitates were washed with ice-cold 75% ethanol and resuspended in
sterile water.
RNA was isolated from the same mouse tissues and from cell cultures using
Trizol (Invitrogen) and cleaned by RNeasy Mini Kit (QIAGEN).
Real-Time PCR Assays for Alu Sequences
Because assays by UV absorbance of DNA extracts from several tissues did
not provide values accurate enough for the PCR assays, DNA concentration
was measured by diphenylamine reaction (Burton, 1956). Samples of 40 ml
were digested for 1 hr at 37Cwith 3 ml DNase I (Fisher Scientific) in 5 ml DNase
buffer and 2 ml of sterile water. Each sample was diluted with 50 ml of sterile
water, and 200 ml of a stock solution of diphenylamine reagent was added
(1 g diphenylamine [Fisher Scientific] in 100ml glacial acetic acid [Fisher Scien-
tific] and 2.75 ml H2SO4 [Sigma]). The samples were incubated for 21 min at
100C, and absorbance was measured at 595 nm. Standard curves were
prepared with 0.039–1.25 mg/ml calf thymus DNA (Sigma).
Real-time PCR assays for Alu sequences (McBride et al., 2003) were per-
formed in a volume of 50 ml that contained 25 ml Taqman Universal PCRMaster
Mix (Applied Biosystems), 900 nM each of the forward and reverse primers,
250 nM TaqMan probe, and 200 ng target template (see the Supplemental
Data for sequences of primers and probes). Reactions were incubated at
50C for 2 min and at 95C for 10 min followed by 40 cycles at 95C for 15 s
and 60C for 1 min. Standard curves were generated by adding serial dilutions
of hMSCs into mouse tissue samples just prior to homogenization. Real-time
PCR assays for human and mouse genes for GAPDH were performed in
a volume of 50 ml that contained 25 ml SYBR Green Master Mix (Applied Bio-
systems), 200 nM each of the forward and reverse primers, and 200 ng target
template. All real-time PCR assays were performed in duplicate or triplicate,
and average values are presented. The final value for total DNA in the sample
was corrected by parallel real-time PCR assays with primers that amplified
both the human and the mouse gene for GAPDH (NCBI home page, http://
www.ncbi.nlm.nih.gov/geo/; Supplemental Data).
Real-Time RT-PCR Assays for mRNA for Human GAPDH
Standard curves were generated by adding serial dilutions of hMSCs tomouse
tissue samples just prior to homogenization. About 200 ng of total RNA was
used to synthesize double-stranded cDNA by reverse transcription (Super-
Script III; Invitrogen). cDNA was analyzed by real-time PCR (ABI 7900
Sequence Detector, Applied Biosystems) with human-specific GAPDH
primers and probe (TaqMan Gene Expression Assays ID, Hs00266705_g1)
using Taqman Universal PCRMaster Mix (Applied Biosystems). The final value
for total cDNA in the sample was corrected by parallel real-time PCR assays
with primers that amplified both the human and the mouse genes for GAPDH
(see the Supplemental Data).
Assays of mRNAs in Lung by Microarrays
RNA was isolated from lungs of mice, assayed on both mouse (MG-430 2.0)
and human (HG-U133 Plus 2.0) microarrays (Affymetrix, Santa Clara, CA),
and the data filtered as described in the Supplemental Data.
Real-Time RT-PCR Analysis for Selected mRNAs
About 200 ng of total RNA was used to synthesize double-stranded cDNA by
reverse transcription (SuperScript III; Invitrogen). cDNA was analyzed by real-
time PCR using Taqman Universal PCR Master Mix (Applied Biosystems). For
the assays, reactions were incubated at 50C for 2 min, 95C for 10 min, and
then 40 cycles at 95C for 15 s followed by 60C for 1 min. For relative quan-
titation of gene expression, human-specific GAPDH primers and probe (Taq-
Man Gene Expression Assays ID, Hs00266705_g1) were used. All other PCR
primer and probe sequences are listed in the Supplemental Data.
Transfections with TSG-6 siRNA
Target hMSCs for the transfections were prepared with viable passage
1 hMSCs that were plated at 50,000 cells/well in CCM in 6-well plates. After
incubation for 1 day, cells were transfected with 10 or 20 nM siRNA for TSG-
6 (sc-39819; Santa Cruz Biotechnology, Santa Cruz, CA) or RNAi-negative
Cell Stem Cell
I.v. hMSCs Embolize and Activate to Express TSG-6control (Stealth RNAi negative Control; Invitrogen) using a commercial kit
(Lipofectamine RNAiMAX reagent; Invitrogen). Six hours later, the medium
was replaced with 3 ml per well of CCM lacking antibiotics, and hMSCs
were incubated for 16–20 hr.
TSG-6 ELISA
TSG-6 protein levels in medium from TNF-a-treated MSCs were determined
by ELISA. A 96-well plate (Maxisorp; Nunc) was coated overnight at 4C
with 50 ml of 10 mg/ml monoclonal antibody specific for TSG-6 (clone
A38.1.20; Santa Cruz Biotechnology, Inc.) in 0.2 M sodium bicarbonate buffer
(pH 9.2). The plates were washed with PBS and blocked with 0.25% (wt/vol)
BSA and 0.05% (vol/vol) Tween 20 in PBS for 30 min at room temperature.
Plateswere againwashedwith PBS. Samples of 50 ml or standards of recombi-
nant human TSG-6 protein (R&D Systems) in blocking buffer were added. After
2 hr at room temperature, wells were washed with PBS followed by 50 ml/well
of 0.5 mg/ml biotinylated anti-human TSG-6 (TSG-6Biotinylated PAbDetection
Antibody; R&D Systems). After 2 hr, plates were washed with PBS. Fifty micro-
liters streptavidin-HRP (R&D Systems) was added to each well. The plate was
covered and incubated for 20 min at room temperature. One hundred microli-
ters substrate solution (R&D Systems) was added, and the sample was
incubated for 10 min at room temperature. Absorbance was read at 450 nm
(Fluostar Optima; BMG Labtechnologies).
Permanent Ligation of the Anterior Descending Coronary Artery
Male immunodeficient NOD/SCID mice (NOD.CB17-Prkdcscid/J; The Jackson
Laboratory) 7–8 weeks of age were ventilated mechanically under anesthesia
with isoflourine, the chest was opened, the left anterior descending coronary
artery was ligated, and the chest was closed. The effectiveness of the LAD
was established in preliminary experiments by the demonstration that serum
cardiac troponin I levels were elevated in 7 mice 48 hr after the surgery
(Figure 4A).
Other Assays
As indicated in the Supplemental Data, commercial kits were used to assay
mouse cardiac troponin I in serum (ELISA kit; Life Diagnostics, Inc.), plasmin
activity in serum (Roche Applied Science), and MMPs in heart by zymography
(10% Zymogram Gelatin Gels; Invitrogen/Novex).
Leukocyte Infiltration Assay in Heart
Frozen heart sections of 5 mm from MI-induced mice were stained with anti-
Ly-6G and Ly-6C (RB6-8C5, BD Biosciences), and Ly-6G- and Ly-6C-positive
cells were counted with a software program (ImageJ, NIH Image).
Microscopic Examination of the Myocardium
Paraffin-embedded heart samples at 21 days after MI were cut into over 400
sequential 5 mm sections and stained with Masson Trichrome. Quantitative
assays for infarct size were performed as described by Takagawa et al.
(2007). In brief, images of every tenth section covering the region of infarct
(total of 20 sections per heart) were examined with a spinning disc microscopy
(Olympus) using a34 objective and capturedwith Stereo Investigator software
(Stereo Investigator version 7; MBF Bioscience). Stereological quantification
software was used to measure midline infarct length of heart.
Echocardiography
Echocardiography (Acuson Sequoia C512 echocardiography system,
Siemens Medical Solutions USA, Inc.) was performed 21 days after MI.
Statistical Analyses
Comparisons between two groups were made with the use of unpaired and
two-tailed Student’s t tests. p < 0.05 was considered significant.
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